NCT03999554 - Safety and Immunogenicity of the Bris10 M2SR and Sing2016 M2SR H3N2 Monovalent Influenza Vaccines | Biotech Hunter

Enrollment

206

Participants

Timeline

Start Date

September 3, 2019

Primary Completion Date

July 1, 2020

Study Completion Date

July 1, 2020

Conditions

Influenza A

Interventions

BIOLOGICAL

LD Sing2016 M2SR H3N2 influenza vaccine

This group will receive a low dose of the Sing2016 M2SR H3N2 monovalent influenza vaccine administered intranasally.

BIOLOGICAL

MD Sing2016 M2SR H3N2 influenza vaccine

This group will receive a medium dose of the Sing2016 M2SR H3N2 monovalent influenza vaccine administered intranasally.

BIOLOGICAL

HD Sing2016 M2SR H3N2 influenza vaccine

This group will receive a high dose of the Sing2016 M2SR H3N2 monovalent influenza vaccine administered intranasally.

BIOLOGICAL

LD Bris10 M2SR H3N2 influenza vaccine

This group will receive a low dose of the Bris10 M2SR H3N2 monovalent influenza vaccine administered intranasally.

OTHER

Placebo

This group will receive saline placebo administered intranasally.

Trial Locations (4)

AMR Norfolk, Norfolk

RCA, Hollywood

AMR Lexington, Lexington

JCCT, Lenexa